Jeff Elkins, a seasoned medtech executive with experience in both startups and larger companies, was recently hired as chief operating officer of InterVene, a Fogarty Institute graduate that has developed a minimally invasive device for the treatment of venous disease in the legs.
Fogarty Institute graduate Alydia Health, formerly known as InPress Technologies, is well on its way to conducting a pivotal study, thanks to the closing of a recent $10M Series B round led by Global Health Investment Fund. The U.S. study aims to prove the safety and efficacy of its novel device, the Jada System, in stopping postpartum hemorrhage (PPH) —
Each year, the caliber of professionals who participate in the Ferolyn Fellowship continues to impress us. Hailing from diverse parts of the healthcare spectrum, they all share an undeniable passion for the medtech industry, coupled with curiosity and the tenacity to solve large problems. In addition, it’s clear that they desire to be part of a community committed to not only accelerating their own career path,
Fogarty Institute graduate InterVene, a startup that has developed a minimally invasive device for the treatment of venous disease in the legs, has treated the 10th patient in their ongoing, multi-center, feasibility study in New Zealand and Australia.
Among the hottest topics in healthcare is the “operating room of the future,” which is on the brink of transformation as new technologies such as artificial intelligence (AI), voice recognition, digital technology and augmented reality are integrated.
And at the forefront is EchoPixel, a Fogarty Institute graduate that has created an interactive,
“There is a better way” is a common mantra heard frequently in discussions between Fogarty Institute mentors and its entrepreneurs. It’s what drives us each day to devise and create new technologies that will transform patient care. And while the process is not always easy, there is nothing more rewarding than seeing a successful patient outcome as a result of a device that was created right here,